Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Llanos-González (SANTA CRUZ DE TENERIFE, Spain), S. García Gil (SANTA CRUZ DE TENERIFE, Spain), J. Bonilla Arjona (SANTA CRUZ DE TENERIFE, Spain), S. García Hernández (SANTA CRUZ DE TENERIFE, Spain), V. Hernández García (SANTA CRUZ DE TENERIFE, Spain), P. Pérez De Armas (SANTA CRUZ DE TENERIFE, Spain), N. Mesa León (SANTA CRUZ DE TENERIFE, Spain), O. Acosta Fernández (SANTA CRUZ DE TENERIFE, Spain). Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF. 2375

Member's Comments

No comment yet.

Related content which might interest you: Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Diagnostic utility of surgical lung biopsies in elderly patients with interstitial lung diseases Source: International Congress 2015 – New insights into IIPs Year: 2015 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Efficacy of pulmonary rehabilitation in patients with interstitial lung disease Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012 Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 The clinical value of surgical lung biopsy in 166 patients with suspected interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Are the gains due to pulmonary rehabilitation in idiopathic pulmonary fibrosis and other interstitial lung diseases the same? Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020 Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013 The management of children with interstitial lung disease Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2016 Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013